Format

Send to

Choose Destination
Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F241-8. doi: 10.1152/ajprenal.00500.2015. Epub 2016 May 18.

Hippo signaling in the kidney: the good and the bad.

Author information

1
Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York.
2
Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York kirk.campbell@mssm.edu.

Abstract

The Hippo signaling pathway is an evolutionarily conserved kinase cascade, playing multiple roles in embryonic development that controls organ size, cell proliferation, and apoptosis. At the center of this network lie the Hippo kinase target and downstream pathway effector Yes-associated protein (YAP) and its paralog TAZ. In its phosphorylated form, cytoplasmic YAP is sequestered in an inactive state. When it is dephosphorylated, YAP, a potent oncogene, is activated and relocates to the nucleus to interact with a number of transcription factors and signaling regulators that promote cell growth, differentiation, and survival. The identification of YAP activation in human cancers has made it an attractive target for chemotherapeutic drug development. Little is known to date about the function of the Hippo pathway in the kidney, but that is rapidly changing. Recent studies have shed light on the role of Hippo-YAP signaling in glomerular and lower urinary tract embryonic development, maintenance of podocyte homeostasis, the integrity of the glomerular filtration barrier, regulation of renal tubular cyst growth, renal epithelial injury in diabetes, and renal fibrogenesis. This review summarizes the current knowledge of the Hippo-YAP signaling axis in the kidney under normal and disease conditions.

KEYWORDS:

Hippo; kidney; podocyte

PMID:
27194720
PMCID:
PMC5005280
DOI:
10.1152/ajprenal.00500.2015
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center